Experience in Germany with Glycyrrhizinic Acid for the Treatment of Chronic Viral Hepatitis

Wildhirt, E

doi:10.1007/978-4-431-68255-4_172

Cited by 9 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A glycyrrhizin product, Stronger Neo‐Minophagen C (SNMC; Minophagen Pharmaceutical, Tokyo, Japan), is used widely in Japan and has been reported to improve ALT levels and liver inflammation 161,162 . Furthermore, Ikeda et al.…”

Section: Consensus On Therapeutic Strategy For Ch‐cmentioning

confidence: 99%

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

Izumi

Nishiguchi

Hino

et al. 2010

Hepatology Research

View full text Add to dashboard Cite

The consensus meeting for the diagnosis, management and treatment for hepatitis C was held in 45(th) annual meeting for the Japan Society of Hepatology (JSH) in June 2009 where the recommendations and informative statements were discussed including organizers and presenters. The Several important informative statements and recommendations have been shown. This was the fourth JSH consensus meeting of hepatitis C, however, the recommendations have not been published in English previously. Thus, this is the first report of JSH consensus of hepatitis C. The rate of development of hepatocellular carcinoma (HCC) in HCV-infected patients in Japan is higher than in the USA, because the average age of the HCV-infected patients is greater and there are more patients with severe fibrosis of the liver than in the USA. In Japan, more than 60% of HCV-infected patients are genotype 1b infection, and they show lower response to perinterferon and ribavirin combination treatment. To improve the response rate is also an important issue in our country. To establish the original recommendations and informative statements to prevent the development of HCC is a very important issue in Japan.

show abstract

Section: Consensus On Therapeutic Strategy For Ch‐cmentioning

confidence: 99%

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

Izumi

Nishiguchi

Hino

et al. 2010

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…A glycyrrhizin-containing product, Stronger NeoMinophagen C (SNMC; Minophagen Pharmaceutical Co. Ltd., Tokyo, Japan), is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in patients with hepatitis B virus and HCVinduced chronic hepatitis. Glycyrrhizin has been reported to suppress hepatic inflammation with an effect to improve the elevated ALT levels and histologic findings of the liver (14)(15)(16)(17). We reported its favorable effect on hepatocellular carcinogenesis in those patients with chronic hepatitis C who received glycyrrhizin for more than 10 years (18).…”

mentioning

confidence: 99%

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

et al. 2006

View full text Add to dashboard Cite

To elucidate the influence of a glycyrrhizin therapy on hepatocarcinogenesis rate in interferon (IFN)-resistant hepatitis C, we retrospectively analyzed 1249 patients with chronic hepatitis with or without cirrhosis. Among 346 patients with high alanine transaminase value (twice or more of upper limit of normal), 244 patients received intravenous glycyrrhizin injection and 102 patients did not, after judgment of IFN resistance. Crude carcinogenesis rates in the treated and untreated group were 13.3%, 26.0% at the 5th year, and 21.5% and 35.5% at the 10th year, respectively (P = .0210). Proportional hazard analysis using time-dependent covariates disclosed that glycyrrhizin treatment significantly decreased the hepatocarcinogenesis rate (hazard ratio 0.49, 95% confidence interval 0.27-0.86, P = .014) after adjusting the background features with significant covariates. Glycyrrhizin injection therapy significantly decreased the incidence of hepatocellular carcinoma in patients with IFN-resistant active chronic hepatitis C, whose average aminotransferase value was twice or more of upper limit of normal after interferon.

show abstract

“…It has been suggested that GL (a natural prodrug and sweet principal of Glycyrrhiza) and its hydrolytic metabolites (GAMA, GA) bind to hepatocytes to modify the expression of HBV (hepatitis B virus)-related antigens and suppress sialylation of hepatitis B virus surface antigen (HbsAg) [34,42]. Clinical studies showed that GL has comparable antiviral effects to those of interferon and that it is effective in reducing complications of chronic hepatitis C without apparent side-effects [43,44]. …”

Section: Biological Activities Of Extracts and Ingredients Of Medicinmentioning

confidence: 99%

A survey of Chinese herbal ingredients with liver protection activities

et al. 2007

View full text Add to dashboard Cite

A literature survey was conducted on herbs, their preparations and ingredients with reported liver protection activities, in which a total of 274 different species and hundreds of active ingredients have been examined. These ingredients can be roughly classified into two categories according to their activities: (1) the main ingredients, such as silybin, osthole, coumarin, glycyrrhizin, saikosaponin A, schisandrin A, flavonoids; and (2) supporting substances, such as sugars, amino acids, resins, tannins and volatile oil. Among them, some active ingredients have hepatoprotective activities (e.g. anti-inflammatory, anticancer, antioxidant, immunomodulating and liver cirrhosis-regulating effects). Calculation of physicochemical parameters indicates that the main ingredients with negative and positive Elumo values possibly display their hepatoprotective effects through different mechanisms, such as antioxidative, anti-inflammatory and immunomodulating effects. As the combination of herbs may achieve some treatment effects synergistically and/or additively, it is common in Chinese medicine to use mixtures of various medicinal herbs with pharmacologically active compounds to have synergistic and/or additive effects, or to reduce harmful effects of some pharmacologically active compounds. In particular, the active compounds with Clog P around 2 are suitable for passive transport across membranes and accessible to the target sites. Thus, Elumo and Clog P values are good indicators among the calculated parameters.Seven different physicochemical parameters (MW, Clog P, CMR, μ, Ehomo, Elumo and Hf) and four major biological activities (antioxidant, anti-inflammatory, antiviral/antitumor and immunomodulating) are discussed in this review. It is hoped that the discussion may provide some leads in the development of new hepatoprotective drugs.

show abstract

Experience in Germany with Glycyrrhizinic Acid for the Treatment of Chronic Viral Hepatitis

Cited by 9 publications

References 0 publications

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

A survey of Chinese herbal ingredients with liver protection activities

Contact Info

Product

Resources

About